ACERUS OTC Stock Buy Hold or Sell Recommendation

ASPCF -  USA Stock  

USD 0.03  0.0018  6.38%

Assuming the 90 days horizon and your typical level of risk aversion, our recommendation regarding ACERUS PHARMACEUTICALS CORP is 'Strong Sell'. Macroaxis provides ACERUS PHARMACEUTICALS buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ASPCF positions. The advice algorithm takes into account all of ACERUS PHARMACEUTICALS's available fundamental, technical, and predictive indicators you will find on this site.

ACERUS Advice 

The advice is provided from ACERUS PHARMACEUTICALS's buy-and-hold perspective. Please continue to ACERUS PHARMACEUTICALS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as ACERUS and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards ACERUS PHARMACEUTICALS CORP.


The ACERUS recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ACERUS PHARMACEUTICALS CORP. Macroaxis does not own or have any residual interests in ACERUS PHARMACEUTICALS CORP or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ACERUS PHARMACEUTICALS's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Strong Sell


Out of controlDetails

Hype Condition


Current Valuation


Odds of Distress

Quite HighDetails

Economic Sensitivity

Responds to the marketDetails

Analyst Consensus

Not AvailableDetails

Reporting Quality (M-Score)

For the selected time horizon ACERUS PHARMACEUTICALS CORP has a Mean Deviation of 6.4, Semi Deviation of 9.14, Standard Deviation of 11.26, Variance of 126.83, Downside Variance of 245.49 and Semi Variance of 83.5
We provide trade advice to complement the prevailing expert consensus on ACERUS PHARMACEUTICALS. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at this time. To make sure ACERUS PHARMACEUTICALS is not overpriced, please confirm all ACERUS PHARMACEUTICALS fundamentals, including its cash and equivalents, number of employees, and the relationship between the gross profit and current ratio . As ACERUS PHARMACEUTICALS appears to be a penny stock we also recommend to validate its cash and equivalents numbers.

ACERUS PHARMACEUTICALS Trading Alerts and Improvement Suggestions

ACERUS PHARMACEUTICALS has very high historical volatility over the last 90 days
ACERUS PHARMACEUTICALS has some characteristics of a very speculative penny stock
ACERUS PHARMACEUTICALS has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 13.16 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. ACERUS PHARMACEUTICALS has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported the revenue of 1.56 M. Net Loss for the year was (34.05 M) with loss before overhead, payroll, taxes, and interest of (929 K).
ACERUS PHARMACEUTICALS CORP has accumulated about 2.6 M in cash with (23.57 M) of positive cash flow from operations.
Roughly 91.0% of ACERUS PHARMACEUTICALS shares are held by company insiders
Latest headline from Testosterone Replacement Therapy Market Is Thriving Worldwide with AbbVie, Bayer AG, Endo Pharmaceuticals, Eli Lilly and Company Otterbein 360 - Otterbein 360

ACERUS PHARMACEUTICALS Returns Distribution Density

The distribution of ACERUS PHARMACEUTICALS's historical returns is an attempt to chart the future uncertainty of ACERUS PHARMACEUTICALS's future price movements. The chart of the probability distribution of ACERUS PHARMACEUTICALS stock daily returns describes the distribution of returns around its average expected value. We use ACERUS PHARMACEUTICALS CORP price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ACERUS PHARMACEUTICALS returns is essential to provide solid investment advice for ACERUS PHARMACEUTICALS stock.
Mean Return0.18Value At Risk-25
Potential Upside20.33Standard Deviation11.26
 Return Density 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ACERUS PHARMACEUTICALS historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.


Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ACERUS PHARMACEUTICALS or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ACERUS PHARMACEUTICALS stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ACERUS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW1.29
Overall volatility
Information ratio 0.015


ACERUS PHARMACEUTICALS CORP is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about ACERUS PHARMACEUTICALS implied risk. ACERUS PHARMACEUTICALS CORP is a penny stock. Although ACERUS PHARMACEUTICALS may be in fact a good investment, many penny otc stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in ACERUS PHARMACEUTICALS CORP. We encourage investors to look for the signals such us message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on ACERUS instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.


Comparing ACERUS PHARMACEUTICALS's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ACERUS PHARMACEUTICALS's direct or indirect competition across all of the common fundamentals between ACERUS PHARMACEUTICALS and the related equities. This way, we can detect undervalued stocks with similar characteristics as ACERUS PHARMACEUTICALS or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of ACERUS PHARMACEUTICALS's fundamental indicators could also be used in its relative valuation, which is a method of valuing ACERUS PHARMACEUTICALS by comparing valuation metrics with those of similar companies.
 Better Than Average     
 Worse Than Average Compare ACERUS PHARMACEUTICALS to competition
Return On Asset(103.13) %(0.14) %
Current Valuation66.52 M16.62 B
Shares Outstanding1.54 B571.82 M
Shares Owned by Insiders91.38 %10.09 %
Price to Book13.85 X9.51 X
Price to Sales27.30 X11.42 X
Revenue1.56 M9.43 B
Gross Profit(929 K)27.38 B
EBITDA(25.5 M)3.9 B
Net Income(34.05 M)570.98 M
Cash and Equivalents2.6 M2.7 B
Total Debt13.16 M5.32 B
Debt to Equity2.61 %48.70 %
Current Ratio0.67 X2.16 X
Cash Flow from Operations(23.57 M)971.22 M
Earnings Per Share(0.03) X3.12 X
Number of Employees1018.84 K
Market Capitalization42.59 M19.03 B
Z Score1.88.72


When is the right time to buy or sell ACERUS PHARMACEUTICALS CORP? Buying financial instruments such as ACERUS OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although ACERUS PHARMACEUTICALS investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having ACERUS PHARMACEUTICALS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Furniture Thematic Idea Now

Furniture Theme
Companies producing and selling home and office furniture. Furniture theme has 19 constituents.
View All  Next Launch Furniture
Please continue to ACERUS PHARMACEUTICALS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the ACERUS PHARMACEUTICALS information on this page should be used as a complementary analysis to other ACERUS PHARMACEUTICALS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for ACERUS OTC Stock analysis

When running ACERUS PHARMACEUTICALS price analysis, check to measure ACERUS PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACERUS PHARMACEUTICALS is operating at the current time. Most of ACERUS PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of ACERUS PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ACERUS PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of ACERUS PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
The market value of ACERUS PHARMACEUTICALS is measured differently than its book value, which is the value of ACERUS that is recorded on the company's balance sheet. Investors also form their own opinion of ACERUS PHARMACEUTICALS's value that differs from its market value or its book value, called intrinsic value, which is ACERUS PHARMACEUTICALS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACERUS PHARMACEUTICALS's market value can be influenced by many factors that don't directly affect ACERUS PHARMACEUTICALS underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACERUS PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine ACERUS PHARMACEUTICALS value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACERUS PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.